nelfinavir has been researched along with sirolimus in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Fridell, JA; Fung, J; Gadomski, M; Jain, AK; Korecka, M; Ragni, M; Shaw, LM; Venkataramanan, R | 1 |
| Fazzari, MJ; Gordon, S; Kuo, PY; Leshchenko, V; Parekh, S; Petrich, AM; Sparano, JA; Thirukonda, VK; Ulahannan, N; Xia, B; Ye, BH | 1 |
| Andrade, MF; Bowers, RR; Delaney, JR; Jones, CM; Voelkel-Johnson, C; White-Gilbertson, S | 1 |
2 review(s) available for nelfinavir and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
4 other study(ies) available for nelfinavir and sirolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report.
Topics: Adult; Female; Graft Rejection; HIV Infections; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Liver Failure; Liver Transplantation; Nelfinavir; Osmolar Concentration; Sirolimus | 2002 |
Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Profiling; Heterocyclic Compounds, 3-Ring; HIV Protease Inhibitors; Humans; Immunoenzyme Techniques; Lymphoma, Large B-Cell, Diffuse; Nelfinavir; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs).
Topics: Apoptosis; Autophagy; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Docetaxel; Female; Giant Cells; Humans; Hydroxychloroquine; Nelfinavir; Ovarian Neoplasms; Polyploidy; Sirolimus | 2022 |